TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

X Jiang, Y Xu, L Yuan, L Zhang, M Huang… - Acta Pharmacologica …, 2021 - nature.com
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …
被引用次数：40 相关文章

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.

XM Jiang, YL Xu, LW Yuan, LL Zhang… - Acta Pharmacologica …, 2020 - europepmc.org
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …

[引用][C] TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

X Jiang, Y Xu, L Yuan, L Zhang, M Huang… - Acta Pharmacologica …, 2020 - cir.nii.ac.jp
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation
contribute to osimertinib resistance | CiNii Research CiNii 国立情報学研究所 学術情報 …

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

XM Jiang, YL Xu, LW Yuan… - Acta …, 2021 - pubmed.ncbi.nlm.nih.gov
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

XM Jiang, YL Xu, LW Yuan, LL Zhang, MY Huang… - 2020 - repository.um.edu.mo
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …
[HTML] nih.gov

[HTML][HTML] TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

X Jiang, Y Xu, L Yuan, M Huang, Z Ye… - Acta Pharmacologica …, 2021 - ncbi.nlm.nih.gov
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …

TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance

L Zhang, H Zhu, RD Ye - 2020 - repository.um.edu.mo
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …

TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance.

XM Jiang, YL Xu, LW Yuan, LL Zhang… - Acta Pharmacologica …, 2020 - europepmc.org
Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …